PanGen Biotech Expands Cell-Based Bioassay Services to Strengthen Competitiveness

- Secured Service Contracts for Huons Pipeline Leveraging Platform Technology -

PanGen Biotech, a subsidiary of the Huons Group, is expanding its cell-based bioassay service business after securing new bioassay service contracts.

PanGen Biotech announced on the 1st that it has recently been awarded contracts from Huons to conduct bioassays for Liraglutide and Semaglutide.

Bioassays are tests that evaluate the potency of pharmaceuticals using living cells and constitute a critical quality control procedure performed for each production batch.

In particular, cell-based bioassays require a high level of expertise and technical capability throughout the entire process, including the selection of appropriate cell lines, optimization of drug concentrations, design of detection mechanisms, and data interpretation.

Leveraging its extensive experience in the research and development of biopharmaceuticals, including erythropoietin (EPO) biosimilars, PanGen Biotech has established robust cell-based analytical capabilities with high accuracy and reproducibility. Based on this expertise, the company is strengthening its competitiveness by providing customized analytical services tailored to client needs.

Building on this project, PanGen Biotech plans to further expand its cell-based bioassay and analytical method validation service businesses. The company also aims to broaden its efficacy evaluation services beyond biopharmaceuticals to encompass a wider range of pharmaceutical products.

PanGen Biotech has been actively engaged in its contract development and manufacturing organization (CDMO) business, underpinned by its proprietary core technology platform, “PANGEN CHO-TECH”. This platform is a protein expression technology optimized for Chinese Hamster Ovary (CHO) cells—widely used in biopharmaceutical production—and encompasses key capabilities in cell line engineering and process development.

PanGen Biotech has completed over 140 cumulative CDMO service projects, having secured contracts from various clients and actively executing these projects. The company currently possesses a total of 41 commercially available biopharmaceutical production cell lines, including 28 cell lines for therapeutic protein production and 13 cell lines for biosimilar antibody production.

A PanGen Biotech representative stated, “We are actively expanding our cell-based bioassay service business. Leveraging the analytical expertise accumulated through our platform technologies, we aim to enhance our clients’ development efficiency and support the generation of highly reliable data.”